From the Editor

Government and private sector efforts take on counterfeit drugs online.

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.

World AIDS Day 2010 reminds us that prevention and hope can help fight the disease.

So 2010 is nearly over and what a year it's been for our industry.

As technology advances, industry's needs are growing.

Connecting science and policy might increase support for innovation.

The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.

Every day we are exposed to messages of advice and guidance on what we can do to reduce the damaging effects that our lifestyles have on the environment.

Industry efforts toward global healthcare surpass average expectations.

New data provide insight into pharma-industry professionals' daily lives.

No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.

Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.

Three therapies under review could help Americans attain a healthy weight.

With more hands in the manufacturing pot, a good contingency plan is crucial to success.

Duke University researchers have found a possible alternative to lyophilization.

After a spate of industrial disasters, the public seeks greater oversight of corporations-so does FDA.

We decided to dedicate this month's issue of PTE to a topic that affects all of our readers; the threat of counterfeit medicines.

Have you ever come across a new technology, process or problem in your profession and wanted to tell others or learn more about it?

FDA wants industry to talk to them about the science underlying process innovations-really.

Agreement on standards for excipient qualification, development, and fair pricing is underway.

Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry.

As the industry continues to evolve, do we know where we're headed?

Change is a part of life which some fear whilst others thrive. In the commercial world, a fundamental aspect of good management is to apply strategic insight to react to change in order to survive and grow. The pharmaceutical industry, as with every industry, is constantly exposed to new threats. Companies are all too painfully aware that the external threats that it currently faces, as well as the threat of their own drying pipelines, are forcing it to adapt and to stay on the lookout for new opportunities - now more than ever.

Contract manufacturers report improving business conditions, but will they continue?

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

Last year, a member of the PTE editorial team attended the 2nd Annual Lyophilisation Conference in London (UK).

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

With the pharmaceutical industry being in a current state of unrest in light of the recent spate of mergers, acquisitions, job cuts, divestments, patent expiries, and so on, we wanted to know how you felt about all these changes that will have directly or indirectly affected you.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

With so many healthcare and pharmacy websites, consumers could use the agency's nod of support.